{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:49:53Z","timestamp":1793875793135,"version":"4.7.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1136\/ijgc-2022-003727","type":"journal-article","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T06:06:46Z","timestamp":1678946806000},"page":"323-332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Outcomes and endpoints of relevance in gynecologic cancer clinical trials"],"prefix":"10.1016","volume":"33","clinical-trial-number":[{"clinical-trial-number":"nct01844986","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02655016","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03709316","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03522246","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02477644","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01874353","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01847274","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01968213","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03635567","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03257267","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03517449","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00942357","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00807768","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00411138","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01874353","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03635567","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03257267","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03555422","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05611931","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7166-9762","authenticated-orcid":false,"given":"Ainhoa","family":"Madariaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Sanchez-Bayona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda G.","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6370-8052","authenticated-orcid":false,"given":"Pedro T.","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8376-9576","authenticated-orcid":false,"given":"Antonio","family":"Gonz\u00e1lez Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2022-003727_bb0010","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.1158\/1078-0432.CCR-19-0619","article-title":"Advancing drug development in gynecologic malignancies","volume":"25","author":"Beaver","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2022-003727_bb0015","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","author":"Biomarkers Definitions Working Group","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1136\/ijgc-2022-003727_bb0020","unstructured":"National Cancer Institute . Available: https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/endpoint [Accessed 20 Oct 2022]."},{"key":"10.1136\/ijgc-2022-003727_bb0025","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/S1470-2045(14)70380-8","article-title":"Outcomes and endpoints in cancer trials: bridging the divide","volume":"16","author":"Wilson","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2022-003727_bb0030","unstructured":"ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) . Available: https:\/\/www.esmo.org\/guidelines\/esmo-mcbs\/about-the-esmo-mcbsAccessed [Accessed 20 Oct 2022]."},{"key":"10.1136\/ijgc-2022-003727_bb0035","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1200\/JCO.2015.61.6706","article-title":"American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options","volume":"33","author":"Schnipper","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2022-003727_bb0040","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1016\/S1470-2045(14)70375-4","article-title":"Outcomes and endpoints in trials of cancer treatment: the past, present, and future","volume":"16","author":"Wilson","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2022-003727_bb0045","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/annonc\/mdw662","article-title":"Fifth ovarian cancer consensus conference of the Gynecologic Cancer InterGroup (GCIG): clinical trial design for rare ovarian tumours","volume":"28","author":"Leary","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2022-003727_bb0050","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1016\/S1470-2045(22)00139-5","article-title":"Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup","volume":"23","author":"Vergote","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2022-003727_bb0055","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1001\/jamaoncol.2022.0864","article-title":"Association of quality-of-life outcomes in cancer drug trials with survival outcomes and drug class","volume":"8","author":"Samuel","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1136\/ijgc-2022-003727_bb0060","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/PPO.0b013e3181b9c602","article-title":"Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials","volume":"15","author":"Buyse","year":"2009","journal-title":"Cancer J"},{"key":"10.1136\/ijgc-2022-003727_bb0065","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.18939","article-title":"Assessment of progression-free survival as a surrogate end point of overall survival in first-line treatment of ovarian cancer: a systematic review and meta-analysis","volume":"3","author":"Paoletti","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1136\/ijgc-2022-003727_bb0070","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","article-title":"Secondary surgical cytoreduction for recurrent ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2022-003727_bb0075","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","article-title":"Randomized trial of cytoreductive surgery for relapsed ovarian cancer","volume":"385","author":"Harter","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2022-003727_bb0080","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1056\/NEJMoa1808424","article-title":"A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms","volume":"380","author":"Harter","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2022-003727_bb0085","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S1470-2045(21)00531-3","article-title":"Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1\/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Banerjee","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2022-003727_bb0090","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.22.01549","article-title":"Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial","volume":"41","author":"DiSilvestro","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2022-003727_bb0095","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2022-003727_bb0100","doi-asserted-by":"crossref","first-page":"S1396","DOI":"10.1016\/j.annonc.2022.08.025","article-title":"LBA29 final overall survival (OS) results from the phase III PAOLA-1\/ENGOT-ov25 trial evaluating maintenance olaparib (OLA) plus bevacizumab (BEV) in patients (PTS) with newly diagnosed advanced ovarian cancer (AOC)","volume":"33","author":"Ray-Coquard","year":"2022","journal-title":"Annals of Oncology"},{"key":"10.1136\/ijgc-2022-003727_bb0105","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2022-003727_bb0110","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2022-003727_bb0115","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1200\/JCO.18.02238","article-title":"Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16\/NOVA trial","volume":"37","author":"Del Campo","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2022-003727_bb0120","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/S0090-8258(21)00693-4","article-title":"Long-term safety and secondary efficacy endpoints in the ENGOT-OV16\/NOVA phase III trial of niraparib in recurrent ovarian cancer","volume":"162","author":"Matulonis","year":"2021","journal-title":"Gynecologic Oncology"},{"key":"10.1136\/ijgc-2022-003727_bb0125","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/S0090-8258(22)01298-7","article-title":"Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME study): a randomized, double-blind, placebo-controlled, phase 3 trial (LBA 5)","volume":"166","author":"Li","year":"2022","journal-title":"Gynecologic Oncology"},{"key":"10.1136\/ijgc-2022-003727_bb0130","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ygyno.2020.06.035","article-title":"Time to first subsequent therapy (TFST) and progression-free survival 2 (PFS2) from the phase 3 randomized, double-blind PRIMA\/ENGOT-OV26\/GOG-3012 study in patients with newly diagnosed ovarian cancer","volume":"159","author":"Han","year":"2020","journal-title":"Gynecologic Oncology"},{"key":"10.1136\/ijgc-2022-003727_bb0135","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ejca.2022.07.022","article-title":"Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: main analysis of second progression-free survival in the phase III PAOLA-1\/ENGOT-ov25 trial","volume":"174","author":"Gonz\u00e1lez Mart\u00edn","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2022-003727_bb0140","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2022-003727_bb0145","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1200\/JCO.22.01003","article-title":"A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO\/GOG-3020\/ENGOT-ov45)","volume":"40","author":"Monk","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2022-003727_bb0150","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S1470-2045(20)30061-9","article-title":"Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial","volume":"21","author":"Ledermann","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2022-003727_bb0155","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2022-ESGO.488","article-title":"2022-RA-249-ESGO\u2005overall survival results from ARIEL3: a phase 3 randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma","author":"Coleman","year":"2022","journal-title":"ESGO 2022 Congress"},{"key":"10.1136\/ijgc-2022-003727_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.07.646","article-title":"518O overall survival results from ARIEL4: a phase III study assessing rucaparib vs chemotherapy in patients with advanced, relapsed ovarian carcinoma and a deleterious BRCA1\/2 mutation","volume":"33","author":"Oza","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2022-003727_bb0165","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/annonc\/mdw663","article-title":"Fifth ovarian cancer consensus conference of the gynecologic cancer intergroup: recurrent disease","volume":"28","author":"Wilson","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2022-003727_bb0170","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/annonc\/mdx011","article-title":"Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions","volume":"28","author":"Karam","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2022-003727_bb0175","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2022-003727_bb0180","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2022-003727_bb0185","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/cpt.1956","article-title":"Relationship between progression-free survival, objective response rate, and overall survival in clinical trials of PD-1\/PD-L1 immune checkpoint blockade: a meta-analysis","volume":"108","author":"Ye","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1136\/ijgc-2022-003727_bb0190","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa2112187","article-title":"Survival with cemiplimab in recurrent cervical cancer","volume":"386","author":"Tewari","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2022-003727_bb0195","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMoa1813181","article-title":"Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer","volume":"380","author":"Matei","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2022-003727_bb0200","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1200\/JCO.18.01575","article-title":"Phase III trial: adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel\/carboplatin in high-intermediate and high-risk early stage endometrial cancer","volume":"37","author":"Randall","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2022-003727_bb0205","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S1470-2045(18)30079-2","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial","volume":"19","author":"de Boer","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2022-003727_bb0210","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv225","article-title":"Design issues in randomized clinical trials of maintenance therapies","volume":"107","author":"Freidlin","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/ijgc-2022-003727_bb0215","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.semcancer.2020.08.013","article-title":"New approaches for targeting platinum-resistant ovarian cancer","volume":"77","author":"McMullen","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"10.1136\/ijgc-2022-003727_bb0220","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.annonc.2022.06.011","article-title":"Efficacy of subsequent chemotherapy for patients with BRCA1\/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2\/ENGOT ov-21 trial","volume":"33","author":"Frenel","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2022-003727_bb0225","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2022-003727_bb0230","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1200\/JCO.2003.01.144","article-title":"Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response","volume":"21","author":"Erasmus","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2022-003727_bb0235","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1136\/ijgc-2021-003319","article-title":"Interobserver and intraobserver variability of RECIST assessment in ovarian cancer","volume":"32","author":"Krasovitsky","year":"2022","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2022-003727_bb0240","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00280-010-1483-x","article-title":"Fulvestrant 250 Mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial","volume":"67","author":"Xu","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1136\/ijgc-2022-003727_bb0245","first-page":"1340","article-title":"Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?","volume":"11","author":"Sznol","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1136\/ijgc-2022-003727_bb0250","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ygyno.2019.11.012","article-title":"Phase 2 study of the exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies","volume":"156","author":"Vergote","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-003727_bb0255","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1158\/1078-0432.CCR-19-0471","article-title":"Everolimus, letrozole, and metformin in women with advanced or recurrent endometrioid endometrial cancer: a multi-center, single arm, phase II study","volume":"26","author":"Soliman","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2022-003727_bb0260","year":"2009","journal-title":"FDA guidance for industry patient-reported outcome measures"},{"key":"10.1136\/ijgc-2022-003727_bb0265","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113296","article-title":"Measuring quality of life in ovarian cancer clinical trials-can we improve objectivity and cross trial comparisons?","volume":"12","author":"Bhat","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1136\/ijgc-2022-003727_bb0270","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1634\/theoncologist.2017-0297","article-title":"A systematic review of health-related quality of life reporting in ovarian cancer phase III clinical trials: room to improve","volume":"23","author":"Wilson","year":"2018","journal-title":"Oncologist"},{"key":"10.1136\/ijgc-2022-003727_bb0275","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1136\/ijgc-2020-001288","article-title":"Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events","volume":"30","author":"Madariaga","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2022-003727_bb0280","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S1470-2045(21)00098-X","article-title":"Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial","volume":"22","author":"Friedlander","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2022-003727_bb0285","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S1470-2045(18)30343-7","article-title":"Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT ov-21): a placebo-controlled, phase 3 randomised trial","volume":"19","author":"Friedlander","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2022-003727_bb0290","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1200\/JCO.19.03107","article-title":"Patient-centered outcomes in ARIEL3, a phase III, randomized, placebo-controlled trial of rucaparib maintenance treatment in patients with recurrent ovarian carcinoma","volume":"38","author":"Oza","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2022-003727_bb0295","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S1470-2045(18)30333-4","article-title":"Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16\/NOVA): results from a double-blind, phase 3, randomised controlled trial","volume":"19","author":"Oza","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2022-003727_bb0300","doi-asserted-by":"crossref","first-page":"S736","DOI":"10.1016\/j.annonc.2021.08.1180","article-title":"738P quality-adjusted time without symptom or toxicity (QA-twist) and quality-adjusted progression-free survival (QA-PFS) of first-line (1L) maintenance niraparib in patients with advanced ovarian cancer (OC): results from the PRiMA trial","volume":"32","author":"Barretina-Ginesta","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2022-003727_bb0305","author":"Madariaga","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-003727_bb0310","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1200\/JCO.21.02017","article-title":"Linking the European Organisation for Research and Treatment of Cancer item library to the common terminology criteria for adverse events","volume":"40","author":"Gilbert","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2022-003727_bb0315","unstructured":"National Cancer Institute . PRO-CTCAE\u00ae. Available: https:\/\/healthcaredelivery.cancer.gov\/pro-ctcae\/overview.html [Accessed 15 Oct 2022]."},{"key":"10.1136\/ijgc-2022-003727_bb0320","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1158\/1078-0432.CCR-09-2167","article-title":"Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents","volume":"16","author":"Dancey","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2022-003727_bb0325","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.annonc.2022.02.223","article-title":"VP2-2022: prospective double-blind, randomized phase III ENGOT-EN5\/GOG-3055\/SIENDO study of oral selinexor\/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer","volume":"33","author":"Vergote","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2022-003727_bb0330","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1200\/JCO.2000.18.8.1733","article-title":"Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials","volume":"18","author":"Rustin","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2022-003727_bb0335","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/bjc.2011.593","article-title":"CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial","volume":"106","author":"Alexandre","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2022-003727_bb0340","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ygyno.2011.11.035","article-title":"Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial","volume":"124","author":"Randall","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-003727_bb0345","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1200\/JCO.22.01207","article-title":"Identification of patients with ovarian cancer experiencing the highest benefit from bevacizumab in the first-line setting on the basis of their tumor-intrinsic chemosensitivity (KELIM): the GOG-0218 validation study","volume":"40","author":"You","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2022-003727_bb0350","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1200\/JCO.22.00430","article-title":"CA-125 KELIM as a potential complementary tool for predicting veliparib benefit: an exploratory analysis from the VELIA\/GOG-3005 study","volume":"41","author":"You","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2022-003727_bb0355","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/1878-0261.12791","article-title":"Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients","volume":"15","author":"Charo","year":"2021","journal-title":"Mol Oncol"},{"key":"10.1136\/ijgc-2022-003727_bb0360","doi-asserted-by":"crossref","DOI":"10.3390\/cells8030200","article-title":"Gynecological cancers translational, research implementation, and harmonization: Gynecologic Cancer InterGroup consensus and still open questions","volume":"8","author":"Bagnoli","year":"2019","journal-title":"Cells"},{"key":"10.1136\/ijgc-2022-003727_bb0365","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1002\/cncr.34331","article-title":"Further refining 2020 ESGO\/ESTRO\/ESP molecular risk classes in patients with early-stage endometrial cancer: a propensity score-matched analysis","volume":"128","author":"Nero","year":"2022","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2022-003727_bb0370","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ygyno.2015.11.030","article-title":"Endpoints in clinical trials: what do patients consider important? A survey of the Ovarian Cancer National Alliance","volume":"140","author":"Minion","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-003727_bb0375","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.ajog.2021.06.071","article-title":"Research biopsies in patients with gynecologic cancers: patient-reported outcomes, perceptions, and preferences","volume":"225","author":"Madariaga","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"10.1136\/ijgc-2022-003727_bb0380","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1158\/2159-8290.CD-21-0003","article-title":"Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy","volume":"12","author":"Herrera","year":"2022","journal-title":"Cancer Discov"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X2400937X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X2400937X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2022-003727","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:18:37Z","timestamp":1753229917000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X2400937X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":75,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1048891X2400937X"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2022-003727","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes and endpoints of relevance in gynecologic cancer clinical trials","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2022-003727","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}